ACA vs JAZZ · P/E 57, rev $2.88B vs P/E 1988, rev $4.07B
Arcosa Inc (ACA) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Arcosa Inc (ACA) is a engineering & construction company listed on US.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Latest reported ACA revenue for 2025-12-31 was $2.88B. Net income was $208.4M. Revenue was up 12.2% from 2024-12-31 to 2025-12-31. ACA currently screens at market cap $4.39B and trailing P/E 56.6.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
ACA currently screens at market cap $4.39B and trailing P/E 56.6. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the ACA and JAZZ stock pages for the full models.
Not investment advice.